ATRA also promotes the survival of tumour‐specific CD8+ T cells, increases the expression of MHC‐I on tumour cells139 and eliminates MDSCs and promotes their differentiation, thereby enhancing anti‐tumour immunity in patients with renal cell carcinoma.140. The gene discussed is CD8A; the disease is neoplasm.